CN101142183A - 有丝分裂驱动蛋白抑制剂 - Google Patents

有丝分裂驱动蛋白抑制剂 Download PDF

Info

Publication number
CN101142183A
CN101142183A CNA2006800081430A CN200680008143A CN101142183A CN 101142183 A CN101142183 A CN 101142183A CN A2006800081430 A CNA2006800081430 A CN A2006800081430A CN 200680008143 A CN200680008143 A CN 200680008143A CN 101142183 A CN101142183 A CN 101142183A
Authority
CN
China
Prior art keywords
alkyl
aryl
cycloalkyl
heterocyclic radical
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800081430A
Other languages
English (en)
Chinese (zh)
Inventor
P·J·科尔曼
C·D·科克斯
G·D·哈特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN101142183A publication Critical patent/CN101142183A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2006800081430A 2005-03-16 2006-03-10 有丝分裂驱动蛋白抑制剂 Pending CN101142183A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66222605P 2005-03-16 2005-03-16
US60/662,226 2005-03-16

Publications (1)

Publication Number Publication Date
CN101142183A true CN101142183A (zh) 2008-03-12

Family

ID=37024314

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800081430A Pending CN101142183A (zh) 2005-03-16 2006-03-10 有丝分裂驱动蛋白抑制剂

Country Status (7)

Country Link
US (1) US7625936B2 (enExample)
EP (1) EP1861366A2 (enExample)
JP (1) JP2008535803A (enExample)
CN (1) CN101142183A (enExample)
AU (1) AU2006227854A1 (enExample)
CA (1) CA2599436A1 (enExample)
WO (1) WO2006101761A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482298A (zh) * 2009-09-11 2012-05-30 亚当密茨凯维奇大学 新型(e)-苯乙烯基-炔基取代的硅化合物和获得(e)-苯乙烯基-炔基取代的硅化合物的方法
CN104892555A (zh) * 2014-03-04 2015-09-09 江苏豪森药业股份有限公司 曲前列尼尔中间体的制备方法
CN111138338A (zh) * 2020-01-20 2020-05-12 中国人民解放军61699部队 一种光催化氟烷基吲哚啉的合成方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629373B2 (en) 2005-04-07 2009-12-08 Merck & Co. Inc. Mitotic kinesin inhibitors
PE20091349A1 (es) 2007-10-19 2009-09-07 Schering Corp Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482298A (zh) * 2009-09-11 2012-05-30 亚当密茨凯维奇大学 新型(e)-苯乙烯基-炔基取代的硅化合物和获得(e)-苯乙烯基-炔基取代的硅化合物的方法
CN102482298B (zh) * 2009-09-11 2015-03-11 亚当密茨凯维奇大学 (e)-苯乙烯基-炔基取代的硅化合物和获得(e)-苯乙烯基-炔基取代的硅化合物的方法
CN104892555A (zh) * 2014-03-04 2015-09-09 江苏豪森药业股份有限公司 曲前列尼尔中间体的制备方法
CN104892555B (zh) * 2014-03-04 2019-03-08 江苏豪森药业集团有限公司 曲前列尼尔中间体的制备方法
CN111138338A (zh) * 2020-01-20 2020-05-12 中国人民解放军61699部队 一种光催化氟烷基吲哚啉的合成方法

Also Published As

Publication number Publication date
EP1861366A2 (en) 2007-12-05
AU2006227854A1 (en) 2006-09-28
CA2599436A1 (en) 2006-09-28
JP2008535803A (ja) 2008-09-04
US7625936B2 (en) 2009-12-01
WO2006101761A3 (en) 2007-03-08
WO2006101761A2 (en) 2006-09-28
US20080194582A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
CN101155583B (zh) 有丝分裂驱动蛋白的抑制剂
JP2006516140A (ja) 有糸分裂キネシン阻害剤
AU2004305069B2 (en) Mitotic kinesin inhibitors
CN101142183A (zh) 有丝分裂驱动蛋白抑制剂
US20080045492A1 (en) Mitotic Kinesin Inhibitors
US7595337B2 (en) Mitotic kinesin inhibitors
CN101005837A (zh) 有丝分裂驱动蛋白抑制剂
CN1980938B (zh) 有丝分裂驱动蛋白抑制剂
US7553838B2 (en) Mitotic kinesin inhibitors
JP2008505089A (ja) 有糸分裂キネシン阻害剤
US7732472B2 (en) Mitotic kinesin inhibitors
AU2004303876A1 (en) Mitotic kinesin inhibitors
US20080207693A1 (en) Mitotic Kinesin Inhibitors
JP2008505090A (ja) 有糸分裂キネシン阻害剤のプロドラッグ
CN1980663A (zh) 有丝分裂驱动蛋白抑制剂的前体药物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080312